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ABSTRACT
Background. This article presents a summary of the 2017 Annual Report of the European Renal Association–European
Dialysis and Transplant Association (ERA-EDTA) Registry and describes the epidemiology of renal replacement therapy
(RRT) for end-stage renal disease (ESRD) in 37 countries.
Methods. The ERA-EDTA Registry received individual patient data on patients undergoing RRT for ESRD in 2017 from 32
national or regional renal registries and aggregated data from 21 registries. The incidence and prevalence of RRT, kidney
transplantation activity and survival probabilities of these patients were calculated.
Results. In 2017, the ERA-EDTA Registry covered a general population of 694 million people. The incidence of RRT for ESRD
was 127 per million population (pmp), ranging from 37 pmp in Ukraine to 252 pmp in Greece. A total of 62% of patients were
men, 52% were 65 years of age and 23% had diabetes mellitus as the primary renal disease. The treatment modality at the
onset of RRT was haemodialysis for 85% of patients. On 31 December 2017, the prevalence of RRT was 854 pmp, ranging
from 210 pmp in Ukraine to 1965 pmp in Portugal. The transplant rate in 2017 was 33 pmp, ranging from 3 pmp in Ukraine
to 103 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2008–12, the unadjusted 5-year patient
survival probability for all RRT modalities combined was 50.8%.
Keywords: dialysis, end-stage renal disease, epidemiology, kidney transplantation, survival analysis
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Table 1. Incidence of RRT in 2017 at Day 1, by country/region, presented as count (n) and unadjusted rate pmp, the mean and median age at
the start of RRT and the number and rate of patients with types 1 and 2 DM as primary renal disease
Country/region
General population covered
by the registry in thousands
Incidence of RRT in 2017, at Day 1
All
(n)
All
(pmp)
Mean
age (years)
Median
age (years)
DM
(n)
DM
(pmp)
Albania 2847 255 90 51.2 52.1 51 18
Austria 8773 1134 129 65.7 68.8 308 35
Belarus 9492 952 100 216 23
Belgium, Dutch-speakinga 6543 1194 182 70.6 73.4 255 39
Belgium, French-speakinga 4832 941 195 68.3 70.7 231 48
Bosnia and Herzegovina 3531 381 108 61.9 63.5 114 32
Bulgaria 7050 1195 170 322 46
Croatia 3713 710 191 67.6 69.0 204 55
Cyprus 864 204 236 68.0 69.0 78 90
Czech Republicb 9920 2301 232
Denmark 5821 761 131 63.8 67.5 198 34
Estonia 1317 87 66 57.0 60.3 16 12
Finland 5508 549 100 60.9 64.9 182 33
France 66 865 11 571 173 67.7 70.5 2678 40
Georgia 3726 782 210 60.9 63.3 194 52
Greece 10 755 2712 252 71.3 74.0 675 63
Iceland 343 49 143 62.2 66.3 4 12
Israel 8713 1683 193 65.6 68.4 779 89
Italy (8 of 20 regions) 26 298 3722 140 68.9 71.8 675 25
Kosovo 1688 321 190 62.9 65.0 104 62
Latvia 1547 177 114 60.9 62.0 29 19
Lithuania 2848 341 120 61.7 62.7 50 18
North Macedonia 2022 365 181 62.7 63.0 100 49
Norway 5277 584 111 63.5 66.9 104 20
Polandb 38 430 6550 170 1470 38
Portugal 10 310 2372 230 753 73
Romania 19 000 3559 187 62.3 64.3 456 24
Russiab 142 473 9495 67 55.8 58.0 1680 12
Serbia 6810 678 100 57.4 62.4 200 29
Slovakiab 5437 927 170 62.0 65.0 344 63
Spain (all regions) 46 572 6567 141 63.5 68.1 1572 34
Spain, Andalusia 8409 1107 132 63.6 66.5 270 32
Spain, Aragon 1315 168 128 64.5 68.6 45 34
Spain, Asturias 1034 161 156 67.0 71.1 41 40
Spain, Basque Country 2169 249 115 63.7 67.2 72 33
Spain, Canary Islands 2166 346 160 63.8 66.1 124 57
Spain, Cantabriaa 581 65 112 64.7 67.5 13 22
Spain, Castile and Leóna 2427 296 122 67.3 68.9 75 31
Spain, Castile-La Manchaa 2037 265 130 66.2 68.5 74 36
Spain, Catalonia 7556 1250 165 66.7 70.3 257 34
Spain, Community of Madrid 6507 865 133 65.0 68.0 228 35
Spain, Extremadura 1080 119 110 63.3 65.3 29 27
Spain, Galicia 2707 416 154 65.2 68.0 97 36
Spain, Murcia 1470 202 137 64.9 67.7 49 33
Spain, Navarrea 642 79 123 65.1 68.4 18 28
Sweden 10 058 1165 116 63.8 67.7 284 28
Switzerland 8452 824 97 65.5 68.8 160 19
The Netherlands 15 932 1839 115 64.5 68.1 370 23
Tunisia, Sfax regionb 990 239 242 62.3 64.0 66 67
Turkeyc 80 811 11 837 146 703 9
UK, Englanda,d 55 619 6649 120 61.9 63.9 1656 30
UK, Northern Irelanda 1871 212 113 63.7 67.7 50 27
UK, Scotland 5425 639 118 59.3 61.9 172 32
UK, Walesa 3125 379 121 62.9 66.3 105 34
Ukraine 42 415 1551 37 52.2 55.0 327 8
All countries 694 024 88 453 127 63.4 66.2 17 935 29
When cells are left empty, the data were unavailable and could not be used for the calculation of the summary data.
aPatients <20 years of age are not reported. The true incidence counts are therefore slightly higher than the counts reported here.
bData include dialysis patients only.
cData on primary renal disease are available for 1893 dialysis patients (16.0%; total n¼11 837).
dThe incidence is underestimated by 2% due to one centre not submitting data since 2014.
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FIGURE 1: Incidence (pmp) of RRT in 2017, at Day 1, by country/region, unadjusted. The incidence for the Czech Republic, Poland, Russia, Slovakia and Sfax region
(Tunisia) only includes patients receiving dialysis. For England (UK), the incidence is underestimated by 2% (Table 1).
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INTRODUCTION
This article is based on the European Renal Association–
European Dialysis and Transplant Association (ERA-EDTA)
Registry’s 2017 Annual Report and presents the most recent
data on the epidemiology of renal replacement therapy (RRT)
for end-stage renal disease (ESRD) in Europe. Data for the year
2017 were received from 53 national or regional renal registries
FIGURE 2: Unadjusted (left panel) and adjusted (right panel) incidence of RRT pmp in 2017, at Day 1, by country/region. Registries providing individual patient data are
shown as dark bars and registries providing aggregated data as light bars. Adjustment of incidence was performed by standardizing the rates to the age and sex distri-
bution of the 27 European Union (EU27) countries’ population. The incidence for the Czech Republic, Poland, Russia, Slovakia and Sfax region (Tunisia) only includes
patients receiving dialysis. For England (UK), the incidence is underestimated by 2% (Table 1).
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from 37 countries in Europe and countries bordering the
Mediterranean Sea [1]. In total, these registries represent a gen-
eral population of 694 million people. When excluding Israel
and Tunisia, the remaining countries cover a general population
of 684.3 million people. This represents 81.1% of the 2017
European general population, which is similar when com-
pared with the 80.5% covered in the 2016 Aannual Rreport [2].
A total of 32 national or regional renal registries from 17 coun-
tries provided individual patient data to the ERA-EDTA
Registry, whereas another 21 countries or regions provided
aggregated data (Appendix 1). Compared with our 2016
Annual Report, the Canary Islands (Spain) are now included
with individual patient data and Kosovo with aggregated
data, whereas data for the Valencia region (Spain) could not
be included this year.
This article presents the 2017 incidence and prevalence of
RRT, kidney transplantation activity and both patient and graft
survival. A detailed description of the methods used to analyse
the data, along with the complete results, can be found in the
ERA-EDTA Registry 2017 Annual Report [1].
RESULTS
Incidence of RRT
In 2017, 88 453 individuals out of a population of 694 million
started RRT for ESRD, resulting in an overall unadjusted inci-
dence of 127 per million population (pmp; Table 1). The unad-
justed incidence ranged from 37, 66 and 67 pmp in Ukraine,
Estonia and Russia, respectively, to 236, 242 and 252 pmp in
Cyprus, the Sfax region (Tunisia) and Greece, respectively
(Table 1; Figures 1 and 2). Of the patients starting RRT, 62%
FIGURE 3: (A) Sex, (B) age and (C) primary renal disease distribution by type of
data provided for incident patients accepted for RRT in 2017, at Day 1. See
Appendix A1 for a list of countries and regions providing individual patient data
or aggregated data.
FIGURE 4: Treatment modality distribution, at Day 1, by (A) type of data pro-
vided, (B) age, (C) sex and (D) primary renal disease (DM and non-DM) for inci-
dent patients accepted for RRT in 2017. (B–D) Based on the data from registries
providing individual patient data. See Appendix A1 for a list of countries and
regions providing individual patient data or aggregated data. Tx, kidney
transplant.
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were men, 52% were 65 years of age and 23% had diabetes
mellitus (DM) as their primary renal disease (Figure 3). The
median age of the patients starting RRT differed by >20 years
between Albania (52.1 years) and Greece (74.0 years; Table 1),
whereas the median age in all countries and regions com-
bined was 66.2 years. The vast majority (85%) of patients
started RRT with haemodialysis (HD), while 11% started with
peritoneal dialysis (PD) and only 4% of patients received a pre-
emptive kidney transplant (Figure 4). Nevertheless, there were
considerable differences in the initial treatment modality be-
tween age groups, with decreasing proportions of patients re-
ceiving either PD or a pre-emptive transplant with increasing
age (Figure 4). Moreover, compared with patients without a
primary renal disease of DM, those with DM more often
started RRT on HD (85% versus 80%) and less frequently re-
ceived a pre-emptive kidney transplant (2% versus 6%).
Among the incident patients receiving RRT at Day 91 after the
start of treatment, 82% were receiving HD, 13% were receiving
PD and 5% were living with a functioning kidney transplant
(Figure 5). When compared with Day 1, the percentage of
patients receiving HD decreased, which was particularly evi-
dent in the younger age groups.
Prevalence of RRT
On 31 December 2017, 592 779 patients were receiving RRT for
ESRD (Table 2), corresponding to an overall unadjusted preva-
lence of 854 pmp. Among the individual countries/regions, the
unadjusted prevalence ranged from 210, 319 and 333 pmp in
Ukraine, Kosovo and Russia, respectively, to 1400, 1427 and 1965
pmp in the Canary Island (Spain), Catalonia (Spain) and
Portugal, respectively (Table 2; Figures 6 and 7). Of the prevalent
patients, 60% were men, 43% were 65 years and 16% had DM
as their primary renal disease (Figure 8). The median age of
prevalent patients receiving RRT in all countries and regions
combined was 62.6 years; in individual countries, it ranged from
50.5 years in Albania to 68.4 years in the Dutch-speaking part of
Belgium and Israel (Table 2). Of prevalent patients, 57% were re-
ceiving HD, 37% were living with a kidney transplant and 5%
were receiving PD (Figure 9). Compared with prevalent patients
without DM as their primary renal disease, those with DM were
less likely to be living with a functioning kidney transplant (51%
versus 28%).
Kidney transplantation
In 2017, 22 902 kidney transplantations were performed, equat-
ing to an overall unadjusted transplant rate of 33 pmp
(Figure 10). In the individual countries/regions, the unadjusted
kidney transplant rates ranged between 3 pmp in Ukraine and
6 pmp in Bulgaria and Kosovo to 79 and 83 pmp in Cantabria
(Spain) and Basque Country (Spain), respectively, and even ex-
ceeding 100 pmp in Catalonia (Spain). Overall, the unadjusted
deceased donor kidney transplant rate was more than twice
that of living donor transplants [23 versus 10 pmp (71% versus
29%); Figures 11 and 12]. The highest unadjusted rates of de-
ceased donor kidney transplants were observed in several
Spanish regions (>70 pmp; Figure 12), whereas the highest
unadjusted rates of living donor transplants were observed in
Northern Ireland (37 pmp), Turkey (33 pmp) and The
Netherlands (31 pmp; Figure 12).
FIGURE 5: Treatment modality distribution, at Day 91, by (A) type of data pro-
vided, (B) age, (C) sex and (D) primary renal disease (DM and non-DM) for inci-
dent patients accepted for RRT in 2017. (B–D) Based on the data from registries
providing individual patient data. See Appendix A1 for a list of countries and
regions providing individual patient data or aggregated data. Tx, kidney
transplant.
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Table 2. Prevalence of RRT on 31 December 2017, by country/region, presented as count (n) and unadjusted rate pmp, mean and median age
on 31 December 2017 and the number and rate of patients with types 1 and 2 DM as primary renal disease
Country/region
General population covered
by the registry in thousands
Prevalent patients on RRT in 2017
All
(n)
All
(Pmp)
Mean
age (years)
Median
age (years)
DM
(n)
DM
(Pmp)
Albania 2847 1557 547 49.5 50.5 331 116
Austria 8773 9540 1087 61.6 63.1 1874 214
Belarus 9492 4295 452 593 62
Belgium, Dutch-speakinga 6543 8419 1287 66.3 68.4 1441 220
Belgium, French-speakinga 4832 6506 1346 65.1 66.8 1177 244
Bosnia and Herzegovina 3531 2644 749 59.7 61.4 520 147
Bulgaria 7050 4421 627
Croatia 3713 4635 1248 65.7 67.0 919 248
Cyprus 864
Czech Republic 9920 11 666 1176
Denmark 5821 5579 958 59.0 60.6 951 163
Estonia 1317 949 720 58.2 58.9 168 128
Finland 5508 5008 909 59.4 61.7 1270 231
France 66 865 87 989 1316 63.0 65.0 14 423 216
Georgia 3726 2972 798 59.8 61.0 590 158
Greece 10 755 14 183 1319 65.0 67.0 2676 249
Iceland 343 261 760 56.4 58.4 26 76
Israelb 8713 6692 768 66.3 68.3 3132 359
Italy (6 of 20 regions) 26 298 30 191 1137 62.6 64.8 3920 148
Kosovo 1688 539 319 63.2 66.0 159 94
Latvia 1547 1058 684 56.4 58.0 102 66
Lithuania 2848 2268 796
North Macedonia 2022 1761 871 59.0 60.0 300 148
Norway 5277 5155 977 59.7 61.7 707 134
Poland 38 430 30 278 788 5200 135
Portugal 10 310 20 259 1965 67.9 68.4 3511 341
Romania 19 000 21 708 1143 61.8 63.6 2189 115
Russia 142 473 47 486 333 54.2 57.0 6696 47
Serbia 6810 4850 712 58.7 61.2 835 123
Slovakiab 5437 3559 655 63.6 66.0 1177 216
Spain (all regions) 46 572 59 810 1284 59.5 62.7 9714 209
Spain, Andalusia 8409 10 296 1224 60.8 62.1 1604 191
Spain, Aragon 1315 1671 1271 63.4 64.7 299 227
Spain, Asturias 1034 1375 1329 63.4 64.5 226 219
Spain, Basque Country 2169 2722 1255 62.1 63.9 318 147
Spain, Canary Islands 2166 3032 1400 61.3 62.5 340 157
Spain, Cantabriaa 581 637 1096 62.3 63.6 92 158
Spain, Castile and Leóna 2427 3031 1249 65.3 66.1 549 226
Spain, Castile-La Manchaa 2037 2422 1189 62.8 63.6 393 193
Spain, Catalonia 7556 10 785 1427 63.2 65.0 1520 201
Spain, Community of Madrid 6507 7537 1158 62.1 63.5 1345 207
Spain, Extremadura 1080 1274 1180 62.0 62.7 194 180
Spain, Galicia 2707 3741 1382 62.9 64.3 627 232
Spain, Murcia 1470 1982 1348 62.4 63.3 283 192
Spain, Navarrea 642 860 1339 62.8 64.3 123 192
Sweden 10 058 9927 987 60.0 62.0 1776 177
Switzerland 8452 7927 938 62.2 64.1 1176 139
The Netherlands 16 617 17 246 1038 60.7 62.6 2308 139
Tunisia, Sfax regionb 990 1007 1018 58.6 60.0 211 213
Turkeyc 80 811 77 311 957 2366 29
UK, Englanda,d 55 619 54 043 972 58.9 59.4 9417 169
UK, Northern Irelanda 1871 1831 979 59.0 58.8 273 146
UK, Scotland 5425 5184 956 56.8 57.8 847 156
UK, Walesa 3125 3161 1011 59.5 60.4 520 166
Ukraine 42 415 8904 210 50.0 51.0 1358 32
All countries 694 709 592 779 854 60.7 62.6 84 853 141
When cells are left empty, the data were unavailable and could not be used for the calculation of the summary data.
aPatients <20 years of age are not reported. The true prevalent counts are therefore slightly higher than the counts reported here.
bData on prevalence include dialysis patients only.
cData on primary renal disease (DM) is based on 6888 dialysis patients (8.9%; total n¼77 311).
dThe prevalence is underestimated by 1% due to one centre not submitting data since 2014.
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FIGURE 6: Prevalence (pmp) of RRT on 31 December 2017 by country/region. The prevalence of Israel, Slovakia and Sfax region (Tunisia) only includes patients receiving
dialysis. For England (UK), the prevalence is underestimated by 1% (Table 2).
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FIGURE 7: Unadjusted (left panel) and adjusted (right panel) prevalence (pmp) of RRT on 31 December 2017 by country/region. Registries providing individual patient
data are shown as dark bars and registries providing aggregated data as light bars. Adjustment of the prevalence was performed by standardizing the prevalence to the
age and sex distribution of the EU27 population. The prevalence of Israel only includes patients receiving dialysis. For England (UK), the prevalence is underestimated
by 1% (Table 2).
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Survival of patients receiving RRT
For patients commencing RRT in the period 2008–12, the 5-year
unadjusted patient survival probability for all RRT modalities
combined was 50.8% [95% confidence interval (CI) 50.7–51.0]. For
patients starting RRT with dialysis in this period, the unad-
justed 5-year patient survival probability was 42.2% (95% CI
42.1–42.4). Adjusted analyses for patient survival on HD and PD
revealed higher survival probabilities in the first 3 years for
those receiving PD (Figure 13). For patients receiving a kidney
transplant in the period 2008–12, living donor transplant recip-
ients experienced a higher adjusted 5-year patient survival
than recipients of deceased donor transplants [94.6% (95% CI
94.2–95.1) versus 92.1% (95% CI 91.8–92.4)], as well as a higher
adjusted 5-year graft survival [86.7% (95% CI 86.0–87.4) versus
81.4% (95% CI 80.9–81.9)]. See Table 3 for a description of the
adjustments made and the countries/regions included in these
analyses.
Expected remaining lifetime
There was a substantial difference in the expected remaining
lifetime between patients receiving dialysis between 2013 and
2017 and the general population (Figure 14). Although patients
living with a functioning kidney transplant have a longer life ex-
pectancy than those receiving dialysis, it is still lower than that
of the age-matched general population. With the advancing age
of kidney transplant recipients, the relative difference in the
expected remaining lifetime compared with the age-matched
general population increases, although the absolute difference
decreases.
FIGURE 8: (A) Sex, (B) age and (C) primary renal disease distribution by type of
data provided for prevalent patients on RRT on 31 December 2017. See Appendix
A1 for a list of countries and regions providing individual patient data or aggre-
gated data.
FIGURE 9: Treatment modality distribution by (A) type of data provided, (B) age,
(C) sex and (D) primary renal disease (DM and non-DM) for prevalent patients on
RRT on 31 December 2017. (B–D) Based on the data from registries providing in-
dividual patient data. See Appendix A1 for a list of countries and regions provid-
ing individual patient data or aggregated data. Tx, kidney transplant.
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FIGURE 10: Kidney transplants performed in 2017, presented as counts and pmp (unadjusted) by country/region. Registries providing individual patient data are shown
as red bars and registries providing aggregated data as orange bars. The total count for Austria is based on residents and non-residents. For Romania, Serbia and
England (UK), the overall kidney transplant rate is underestimated by 30, 15 and 7%, respectively.
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AFFILIATED REGISTRIES
Albanian Renal Registry: M. Barbullushi, A. Idrizi and E.
Bolleku Likaj; Austrian Dialysis and Transplant Registry
(OEDTR): R. Kramar; Belarus Renal Registry: K.S. Komissarov,
K.S. Kamisarau and A.V. Kalachyk; Dutch-speaking Belgian
Society of Nephrology (NBVN): M. Couttenye, F. Schroven and
J. De Meester; French-speaking Belgian Society of Nephrology
(GNFB): J.M. des Grottes and F. Collart; Renal Registry Bosnia
and Herzegovina: H. Resic, B. Jakovljevic and M. Tomic;
Bulgarian Renal Registry: E.S. Vazelov and I. Velinova;
Croatian Registry of Renal Replacement Therapy (CRRRT): I.
Bubic and M. Knotek; Cyprus Renal Registry: K. Ioannou and
all of the renal units providing data; Czech Republic Registry
of Dialysis Patients (RDP): I. Rychlı́k, J. Potucek and F. Lopot;
Danish Nephrology Registry (DNS): J.G. Heaf; Estonian Society
of Nephrology: Ü. Pechter, K. Lilienthal and M. Rosenberg;
Finnish Registry for Kidney Diseases: P. Finne, J. Helve and
P.H. Groop; France – Renal Epidemiology and Information
Network (REIN): M. Lassalle and C. Couchoud; Georgian Renal
Registry: N. Kantaria and Dialysis Nephrology and
Transplantation Union of Georgia; Hellenic Renal Registry: G.
Moustakas; Icelandic End-Stage Renal Disease Registry: R.
Pálsson; Israel National Registry of Renal Replacement
Therapy: R. Dichtiar, L. Keinan-Boker and E. Golan; Italian
Registry of Dialysis and Transplantation (RIDT): A. Limido, M.
Nordio and M. Postorino; Kosovo Renal Registry: H. Korca, S.
Selmani and M. Tolaj-Avdiu; Latvian Renal Registry: H.
Cernevskis, V. Kuzema and A. Popova; Lithuanian Renal
Registry: V. Vainauskas, K. Petruliene and E. Ziginskiené;
Macedonian Renal Registry: O. Stojceva-Taneva and N.
Dimitriova; Norwegian Renal Registry: A.V. Reisæter and A.
Åsberg; Polish Renal Registry: A. DeRbska-Slizien, R. Gellert
and G. Korejwo; Portuguese Renal Registry: F. Macário and A.
Ferreira; Romanian Renal Registry (RRR): G. Mircescu, L.
Garneata and E. Podgoreanu; Russian Renal Registry: N.
Tomilina, A. Andrusev and H. Zakharova; Renal Registry in
Serbia: M. Lausevic, R. Naumovic, all of the Serbian renal
units and the Serbian Society of Nephrology; Slovakian Renal
Registry: V. Spustová, I. Lajdová and M. Karolyova; Spanish
RRT National Registry at ONT, Spanish Regional Registries
and Spanish Society of Nephrology (SEN); Swedish Renal
Registry: M. Stendahl, H. Rydell, M. Evans, K.G. Prütz, T.
Lundgren and M. Segelmark; Swiss Dialysis Registry: P.
Ambühl and R. Winzeler; Dutch Renal Registry (RENINE): L.
Heuveling, S. Vogelaar and M. Hemmelder; Tunisia, Sfax re-
gion: F. Jarraya and D. Zalila; Registry of the Nephrology,
Dialysis and Transplantation in Turkey (TSNNR): G.
Süleymanlar, N. Seyahi and K. Ateş; Ukrainian Renal Data
System (URDS): M. Kolesnyk, S. Nikolaenko and O.
Razvazhaieva; UK Renal Registry: all the staff of the UK Renal
Registry and of the renal units submitting data; Scottish
Renal Registry: all of the Scottish renal units); and the re-
gional registries of Andalusia (SICATA): P. Castro de la Nuez
(on behalf of all users of SICATA); Aragon: F. Arribas Monzón,
J.M. Abad Diez and J.I. Sanchez Miret; Asturias: P. Beltrán, J.R.
Quirós and RERCA Working Group; Basque Country (UNIPAR):
Á. Magaz, J. Aranzabal, M. Rodrigo and I. Moina; Canary
Islands: H. Sánchez Janáriz; Cantabria: J.C. Ruiz San Millán, O.
Garcia Ruiz and C. Pi~nera Haces; Castile and León: M.A.
Palencia Garcı́a; Castile-La Mancha: G. Gutiérrez Ávila and I.
Moreno Alı́a; Catalonia (RMRC): E. Arcos, J. Comas and J. Tort;
Community of Madrid: M.I. Aparicio de Madre; Extremadura:
all the renal units (Nephrology and Dialysis); Galicia: E.
Bouzas-Caama~no; Renal Registry of the Region of Murcia: C.
Santiuste de Pablos and I. Marı́n Sánchez; and Navarre: M.F.
Slon Roblero, J. Manrique Escola and J. Arteaga Coloma.
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(France), M. Nordio (Italy), S.S. Sørensen (Denmark) and E. Vidal
(Italy).
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FIGURE 11: Donor-type distribution for kidney transplants performed in 2017, by
type of data provided. See Appendix A1 for a list of countries and regions provid-
ing individual patient data or aggregated data.
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FIGURE 12: Deceased donor (left panel) and living donor (right panel) kidney transplants performed in 2017 pmp, by country/region, unadjusted. Registries providing in-
dividual patient data are shown as dark bars and registries providing aggregated data as light bars. The total count for Austria is based on residents and non-residents.
For Romania and England (UK), the kidney transplant rate is underestimated by 30 and 7%, respectively. For Serbia, the transplant rate is underestimated by 16% for de-
ceased donor transplants and by 12% for living donor transplants.
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FIGURE 13: Survival of patients starting HD and PD between 2008 and 2012 from Day 91 (left panel) and patients receiving a first kidney transplant from a living or de-
ceased donor between 2008 and 2012 (right panel). Survival on dialysis was censored for kidney transplantation and adjusted using fixed values for age (67 years), sex
(63% men) and primary renal disease (24% DM, 19% hypertension/renal vascular disease, 11% glomerulonephritis and 46% other causes). Survival after kidney trans-
plantation was adjusted using fixed values for age (50 years), sex (63% men) and primary renal disease (14% DM, 10% hypertension/renal vascular disease, 23% glomeru-
lonephritis and 53% other causes). These figures are based on data from the following registries providing individual patient data: Austria, Belgium (Dutch-speaking),
Belgium (French-speaking), Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque Country), Spain
(Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Sweden, The
Netherlands, UK (England, Northern Ireland, Wales) and UK (Scotland).
Table 3. The survival probabilities at 1, 2 and 5 years by treatment modality and cohort from Day 1 of the start of RRT/dialysis or from the day
of kidney transplantation
Survival type
Survival probabilities as a percentage (95% CI)
Cohort: 2008–12 Cohort: 2011–15
1 year 2 years 5 years 1 year 2 years
Patient survival on RRT
Unadjusted 83.9 (83.7–84.0) 73.7 (73.6–73.9) 50.8 (50.7–51.0) 84.8 (84.6–84.9) 74.8 (74.6–74.9)
Adjusteda 86.6 (86.4–86.7) 77.2 (77.0–77.4) 52.4 (52.1–52.7) 87.2 (87.1–87.4) 78.0 (77.8–78.2)
Patient survival on dialysis
Unadjusted 82.8 (82.6–82.9) 71.2 (71.0–71.4) 42.2 (42.1–42.4) 83.6 (83.5–83.8) 72.1 (72.0–72.3)
Adjusteda 84.9 (84.8–85.1) 74.4 (74.2–74.6) 45.7 (45.4–46.1) 85.9 (85.8–86.1) 75.6 (75.4–75.9)
Patient survival after first kidney transplantation (deceased donor)
Unadjusted 96.3 (96.1–96.5) 94.3 (94.0–94.5) 87.3 (87.0–87.6) 96.3 (96.1–96.5) 94.2 (94.0–94.5)
Adjustedb 97.8 (97.7–98.0) 96.6 (96.4–96.8) 92.1 (91.8–92.4) 98.0 (97.9–98.1) 96.8 (96.7–97.0)
Graft survival after first kidney transplantation (deceased donor)
Unadjusted 91.2 (90.9–91.5) 88.3 (88.0–88.6) 78.6 (78.2–79.0) 91.4 (91.1–91.7) 88.3 (88.0–88.6)
Adjustedb 92.6 (92.3–92.9) 90.0 (89.7–90.4) 81.4 (80.9–81.9) 93.1 (92.9–93.4) 90.6 (90.3–91.0)
Patient survival after first kidney transplantation (living donor)
Unadjusted 98.8 (98.6–99.0) 97.9 (97.6–98.2) 93.9 (93.5–94.4) 99.0 (98.8–99.2) 98.1 (97.8–98.3)
ERA-EDTA Registry Annual Report 2017 | 707
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article/13/4/693/5860801 by guest on 02 N
ovem
ber 2020
CONFLICT OF INTEREST STATEMENT
None declared.
REFERENCES
1. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2017.
Amsterdam: Amsterdam UMC, Department of Medical
Informatics, 2019
2. Kramer A, Pippias M, Noordzij M et al. The European Renal
Association–European Dialysis and Transplant Association
(ERA-EDTA) Registry Annual Report 2016: a summary. Clin
Kidney J 2019; 12: 702–720
FIGURE 14: Expected remaining lifetimes of prevalent dialysis and kidney transplant
patients (cohort 2013–17) and the general population (cohort 2013–17), by age. This
figure is based on data from the following registries providing individual patient
data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark,
Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain
(Asturias), Spain (Basque Country), Spain (Cantabria), Spain (Castile and León), Spain
(Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain
(Community of Madrid), Sweden, The Netherlands and UK (all countries).
Table 3. (continued)
Survival type
Survival probabilities as a percentage (95% CI)
Cohort: 2008–12 Cohort: 2011–15
1 year 2 years 5 years 1 year 2 years
Adjustedb 99.0 (98.8–99.2) 98.2 (98.0–98.5) 94.6 (94.2–95.1) 99.2 (99.0–99.3) 98.4 (98.1–98.6)
Graft survival after first kidney transplantation (living donor)
Unadjusted 96.3 (96.0–96.7) 94.6 (94.2–95.0) 87.5 (86.9–88.1) 96.9 (96.5–97.2) 95.1 (94.7–95.5)
Adjustedb 96.1 (95.7–96.5) 94.3 (93.8–94.8) 86.7 (86.0–87.4) 96.7 (96.3–97.0) 94.9 (94.5–95.3)
The findings are based on data from the following renal registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking),
Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque Country), Spain (Cantabria), Spain (Castile and
León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Community of Madrid), Spain (Extremadura), Spain (Galicia), Sweden, The Netherlands, UK (England,
Northern Ireland, Wales) and UK (Scotland).
Unadjusted survival probabilities were calculated using the Kaplan–Meier method and adjusted survival probabilities using the Cox regression model.
aAnalyses were adjusted using fixed values: age (67 years), sex (63% men) and primary renal disease (24% DM, 19% hypertension/renal vascular disease, 11% glomerulo-
nephritis and 46% other causes).
bAnalyses were adjusted using fixed values: age (50 years), sex (63% men) and primary renal disease (14% DM, 10% hypertension/renal vascular disease, 23% glomerulo-
nephritis and 53% other causes).
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Appendix 1
Countries or regions providing individual patient data to the
ERA-EDTA Registry: Austria; Dutch-speaking Belgium; French-
speaking Belgium; Bosnia and Herzegovina; Denmark; Estonia;
Finland; France; Greece; Iceland; Norway; Romania; Serbia; the
Spanish regions of Andalusia, Aragon, Asturias, Basque Country,
Canary Islands, Cantabria, Castile and León, Castile-La Mancha,
Catalonia, Community of Madrid, Extremadura, Galicia, Murcia
and Navarre; Sweden; Switzerland; The Netherlands; UK
(England, Northern Ireland ,Wales and Scotland).
Countries or regions providing aggregated data to the ERA-
EDTA Registry: Albania, Belarus, Bulgaria, Croatia, Cyprus, the
Czech Republic, Georgia, Israel, Italy, Kosovo, Latvia, Lithuania,
North Macedonia, Poland, Portugal, Russia, Slovakia, Spain, Sfax
region (Tunisia), Turkey and Ukraine.
Countries not providing data to the ERA-EDTA Registry:
Andorra, Armenia, Azerbaijan, Germany, Hungary, Ireland,
Liechtenstein, Luxembourg, Malta, Moldova, Monaco, San
Marino and Slovenia.
Appendix 2
Miscellaneous primary renal diseases: nephropathy (interstitial)
due to analgesic drugs, nephropathy (interstitial) due to cis-
platinum, nephropathy (interstitial) due to cyclosporin A, lead-
induced nephropathy (interstitial), drug-induced nephropathy
(interstitial) not mentioned above, cystic kidney disease–type
unspecified, polycystic kidneys– infantile (recessive), medullary
cystic disease, including nephronophthisis, cystic kidney dis-
ease – other specified type, hereditary/familial nephropathy –
type unspecified, hereditary nephritis with nerve deafness
(Alport’s syndrome), cystinosis, primary oxalosis, Fabry’s dis-
ease, hereditary nephropathy – other specified type, renal hypo-
plasia (congenital) – type unspecified, oligomeganephronic
hypoplasia, congenital renal dysplasia with or without urinary
tract malformation, syndrome of agenesis of abdominal
muscles (prune belly), renal vascular disease due to polyarteri-
tis, Wegener’s granulomatosis, ischemic renal disease/choles-
terol embolism, glomerulonephritis related to liver cirrhosis,
cryoglobulinemic glomerulonephritis, myelomatosis/light chain
deposit disease, amyloid, lupus erythematosus, Henoch–
Schönlein purpura, Goodpasture’s syndrome, systemic sclerosis
(scleroderma), haemolytic–uraemic syndrome (including
Moschcowitz syndrome), multisystem disease – other (not men-
tioned above), tubular necrosis (irreversible) or cortical necrosis,
tuberculosis, gout, nephrocalcinosis and hypercalcemic ne-
phropathy, Balkan nephropathy, kidney tumour, traumatic or
surgical loss of kidney and other identified renal disorders.
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